Extensive, international experience in academic, private and global institutions in the fields of leadership, administration and management of higher education, research and development, innovation, and entrepreneurship, as evidenced by:

  • Ability to formulate, plan, design and implement strategic visions and to lead innovative and large-scale programs;
  • Large staff management and leadership;
  • Talent to motivate teams of professionals to perform at their best;
  • Successful leadership and management of large-scale operations; creation of revenue-generating projects; track record of funding from agencies and donors;
  • Worldwide knowledge of teaching, research and administration of science, health and medicine, engineering, education, business, management, and the arts;
  • In-depth knowledge of European, US, UK, Gulf and South Asian university systems;
  • Special interest in achieving strong local, national and international partnerships between public and private sectors;
  • Synthetic mind and lateral thinker; ability to make quick decisions;
  • Enthusiastic team spirit, refined communication skills, and cultural sensitivity;
  • Open to the outside world; flexible and adaptable.

2018-present   Pro-Vice Chancellor (Academic & Research), University of Kurdistan Hewlêr, Erbil, Kurdistan

2009-2018       Founding Co-Director and Vice President; Professor of Biological and Medical Sciences, Centre for Non-Communicable Diseases (CNCD), Karachi, Pakistan

2016-2018       Expert Consultant on Technologies in Higher and Medical Education and Council Member, Gerson Lehrman Group Councils, Austin, TX 7870, USA  

2015-2016       Provost (ESC, Regional Business School and CNCD, School of Sports Management) and Special Advisor to the President, Higher Education, Chamber of Commerce and Industry of the Pau-Bearn Region, France

2013-2015       Founding Vice-Provost for Research; Acting Provost, Nazarbayev University, Astana, Kazakhstan

2011-2013       Dean, School of Arts and Sciences; Professor of Biological and Medical Sciences, Lebanese American University (LAU), Beirut, Byblos, Lebanon; New York City, USA

2009-2011       Dean, College of Arts and Sciences; Acting Provost (July 2009-March 2011); Acting Vice-Chancellor (September 2009-January 2010), Professor of Biological and Medical Sciences, Abu Dhabi University (ADU), Abu Dhabi, United Arab Emirates 

2001-2009       The Abdulaziz Hussainali Shariff endowed Professor and Founding Chairman, Department of Biological and Biomedical Sciences, Medical College, Aga Khan University, Karachi, Pakistan

1993-2001       Associate Professor and Deputy Chair, Department of Pathology, Faculty of Medicine & Health Sciences, UAE University, Al Ain, United Arab Emirates

1991-1992       Consultant, Biotechnology, USA and Japan; Medical and Scientific Writer

1983-1990       Senior Scientist and Director, Division of Molecular Genetics (1987-1990); Staff Scientist and Project Leader (1984-1986); Scientist (1983-1984), California Biotechnology, Inc., Mountain View, CA, USA (now Scios, Inc.)

1981-1983       Medical Fellow, Department of Human Genetics, University of Michigan Medical Center, Ann Arbor, MI, USA

1980-1981       Post-Doctoral Fellow, Department of Biological Chemistry, University Louis Pasteur, Strasbourg, France

1979-1980       Post-Doctoral Fellow, Department of Respiratory Physiology, CNRS and University Louis Pasteur, Strasbourg, France

1977-1979       Lecturer, Biophysics and Physiology, University Louis Pasteur Medical School, Strasbourg, France

Continuously engaged in various ventures with external companies, government agencies, universities and the general public, among which:


Participated, as a member of the senior management team, in the expansion and exposure of California Biotechnology, Inc., a venture-capital company that was based in Mountain View, California, USA, and in leading it to become a Nasdaq -traded company; between 1983 and 1990, the company’s stock price fluctuated between USD 2.5 and 29.75 (stock price shot up from USD 7 to 29.75 upon widespread coverage following the announcement of results on the use of genetic markers in testing for cardio-vascular and other complex, human diseases), its benefits went up from USD 15 to 550 M, and its staff number from 6 to 275;

Between 1985 and 1990, negotiated directly with pharmaceutical and biotechnology companies; interacted personally with governmental agencies (US Congress, Departments of Health and of Trade, Office of Technology Assessment), patent offices, Wall Street market and security analysts, insurance companies, the media (written, radio, TV) and the general public;

Between 1995 and 2001, Senior Consultant Geneticist, Al Ain Medical District;

In 2006-2009, member of the Board of Graduate Studies of the University of Baluchistan, Quetta, Pakistan; all programs were accredited (MS and PhD in Biotechnology, Molecular and Cellular Biology, Computer Sciences; MS in Military Strategy for Quetta’s Joint Command Staff College);

In 2016-2018, business ventures with Indian entrepreneurs and investors (such as Cosmos Group, Delhi, for renewable energy and water management projects in West Africa);

From 2009 until 2018, implementation of cardio-vascular diseases (heart disease, hypertension, diabetes and obesity) awareness campaigns for the general population of Pakistan.

Writer for the general public

Extensive experience as scientific and medical writer for the general public evidenced by numerous (over 50) published articles for newspapers and magazines in Anglo-Saxon and French media.

Interactions with the Media

Numerous interviews in the USA, UK, France, the UAE and Pakistan for the written press: newspapers and magazines (including, among many others, The Wall Street Journal, The New York Times, San Francisco Bay Chronicle, Le Monde, Health Today, L’Express); medical and scientific press (Science, Internal Medicine News, Cardiology News, Agir et Comprendre - Institut Curie); radio stations (US and Europe including, among many others, BBC World Service) numerous appearances on television (US’s ABC, NBC and several others, France’s FR3, UAE’s Dubai Channel; Pakistan’s Dawn Channel).


Publication record goes back to 1981. Selected publications over the past 10 years include the following, among others:

Mahajan A, Wessel J, Willems SM, et al. Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes (Letter). Nature Genetics 2018 Apr; 50(4): 559-571. doi: 10.1038/s41588-018-0084-1.

Liu DJ, Peloso GM, Yu H, et al. Exome-wide association study of plasma lipids in> 300,000 individuals (Letter). Nature Genetics 2017 Dec; 49(12): 1758-1766. doi: 10.1038/ng.3977.

Zhao W, Rasheed A, Tikkanen E, et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease (Letter). Nature Genetics 2017 Oct; 49(10): 1450-1457. doi: 10.1038/ng.3943.

Rannikmäe K, Sivakumaran V, Millar H, et al.; Stroke Genetics Network (SiGN), METASTROKE Collaboration, and International Stroke Genetics Consortium (ISGC). COL4A2 is associated with lacunar ischemic strike and deep ICH: Meta-analyses among 21,500 cases and 40,600 controls. Neurology 2017 Oct 24; 89(17): 1829-1839. doi: 10.1212/WNL.0000000000004560.

Howson JMM, Zhao W, Barnes DR, et al. Fifteen new risk loci for coronary artery disease highlight arterial wall-specific mechanisms (Letter). Nature Genetics 2017 Jul; 49(7): 1113-1119. doi: 10.1038/ng.3874. 2017.

Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. New England Journal of Medicine 2017 Jul 13; 377(2): 111-121. doi: 10.1056/NEJMoa1701719.

Saleheen D, Haycock PC, Zhao W, et al. Apoliprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomization analysis. Lancet Diabetes Endocrinology 2017 Jul; 5(7): 524-533. doi: 10.1016/S2213-8587(17)30088-8.

Saleheen D, Natarajan P, Armean IM, et al. Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity (Letter). Nature 2017, April 12; 544(7649): 235-239. doi: 10.1038/nature22034.

Stitziel NO, Khera AV, Wang X, et al. PROMIS and Myocardial Infarction Genetics Consortium Investigators.ANGPTL3 deficiency and protection against coronary artery disease. Journal of the American College of Cardiology 2017 Apr 25; 69(16): 2054-2063. doi: 10.1016/j.jacc.2017.02.030.

Imamura M, Takahashi A, Yamauchi T, et al. Genome-wide association studies in the Japanese population identify seven novel loci for type 2 diabetes. Nature Communications 2016; 7: 10531.

Surendran P, Drenos F, Young R, et al. Trans-ancestry meta-analyses identify rare and common variants associated with blood pressure and hypertension (Letter). Nature Genetics 2016; 48(10): 1151-61. doi: 10.1038/ng.3654.

NINDS Stroke Genetics Network (SiGN) and International Stroke Genetics Consortium (ISGC). Loci associated with ischaemic stroke and its subtypes (SiGN): a genome-wide association study. Lancet Neurology 2016; 15: 174-184.

Ahmad S, Zhao W, Renström F, et al. A novel interaction between the FLJ33534 locus and smoking in obesity: a genome-wide study of 14 131 Pakistani adults. International Journal of Obesity 2016; 40(1): 186-190.

Keenan T, Zhao W, Rasheed A, et al. Causal assessment of serum urate levels in cardiometabolic diseases through a Mendelian randomization study. Journal of the American College of Cardiology 2016; 67(4): 407-416.

International Stroke Genetics Consortium and NINDS Stroke Genetics Network (SiGN). A genome-wide association study of ischemic stroke and its subtypes identifies a novel locus near TSPAN2 for stroke related to atherosclerosis. Nature Genetics 2015; Sep 7. doi: 10.1038/ng.3396.

Ahmad S, Zhao W, Renström F, et al. Physical activity, smoking, and genetic predisposition to obesity in people from Pakistan: the PROMIS study. BMC Medical Genetics 2015; 16(1): 114.

CARDIoGRAMplusC4D Consortium. A Comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nature Genetics 2015; 47(10): 1121-30.

DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium et al.Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility (Letter). Nature Genetics 2014; 46(3): 234-244.

Saxena R, Saleheen D, Been LF, et al. Genome-Wide Association Study Identifies a Novel Locus Contributing to Type 2 Diabetes Susceptibility in Sikhs of Punjabi Origin From India. Diabetes 2013; 62(5): 1746-1755; doi: 10.2337/db12-1077.

Khan M, Rasheed A, Hashmi S, et al. Stroke radiology and distinguishing characteristics of intracranial atherosclerotic disease in native South Asian Pakistani. International Journal of Stroke 2013; Suppl 100: 14-20. doi: 10.1111/j.1747-4949.2012.00878.x. Epub 2012 Sep 27.

Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomization study. The Lancet 2012; 380(9841): 572-580.

Kelly MA, Rees SD, Hydrie MZ, et al; Diagram Consortium; SAT2D Consortium (225 Collaborators). Circadian gene variants and susceptibility to type 2 diabetes: a pilot study. PLoS One 2012; 7(4): e32670.

Cheng YC, Anderson CD, Bione S, et al; on behalf of the International Stroke Genetics Consortium. Are myocardial infarction-associated single-nucleotide polymorphisms associated with ischemic stroke? Stroke 2012; 43(4): 980-986.

Clarke R, Bennett DA, Parish S, et al; MTHFR Studies Collaborative Group. Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Medicine 2012; 9(2): e1001177.

C-Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: Mendelian randomization analysis based on individual participant data. British Medical Journal 2011; 342: d548.

Kooner JS, Saleheen D, Sim X, et al. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci (Letter). Nature Genetics 2011; 43(10): 984-989.

IBC 50K CAD Consortium (425 Collaborators). Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genetics 2011; 7(9): e1002260.

The Coronary Artery Disease (C4D) Genetics Consortium. A genome-wide association study in Europeans and South Asians reveals five novel loci for coronary artery disease (Letter). Nature Genetics 2011; 43(4): 339-344.

Risk Factors Collaboration. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. The Lancet 2010; 375(9726): 1634-1639.

Saleheen D, Hashmi SK, Zaidi M, et al. Evaluation of therapeutic control in a Pakistani population with hypertension. Journal of Evaluation in Clinical Practice 2010; 16(6): 1081-1084.

Burgess S, Thompson SG, and the CRP CHD Genetics Collaboration. Bayesian methods for meta-analysis of causal relationships estimated using genetic instrumental variables. Statistics in Medicine 2010; 29(12): 1298-1311.

Kamal AK, Taj F, Junaidi B, et al. The Karachi intracranial stenosis study (KISS) protocol: an urban multi-center case-control investigation reporting the clinical, radiologic and biochemical associations of intracranial stenosis in Pakistan. BioMed Central Neurology 2009; 9(1):31.

Saleheen D, Zaidi M, Rasheed A, et al. The Pakistan Risk of Myocardial Infarction Study: a resource for the study of genetic, lifestyle and other determinants of myocardial infarction in South Asia. European Journal of Epidemiology 2009; 24(6): 329-38.

Coronary Artery Disease Consortium. Large scale association analysis of novel genetic loci for coronary artery disease. Arteriosclerosis, Thrombosis and Vascular Biology 2009; 29(5): 774-80.

CRP CHD Genetics Collaboration. Collaborative pooled analysis of data on C-reactive protein gene variants and coronary disease: judging causality by Mendelian randomisation. European Journal of Epidemiology 2008; 23(8): 531-540.

Saleheen D, Ali A, Khanum S, et al. Molecular analysis of the XLRS1 gene in four females affected with X-linked juvenile retinoschisis. Canadian Journal of Ophtalmology 2008; 43(5): 596-599.

Funded Grants (*As Principal Investigator):

*Structural and functional properties of giant annelid multi-subunit erythrocruorins (haemoglobins), Centre National de la Recherche Scientifique (CNRS), Paris, France, 1976-1979, US$ 150,000.

*Conceptualization, design and implementation of a Division of Molecular Genetics for the study of human multi-factorial disorders, Biotechnology Research Partners, US, 1984-1989. Annual budget of US$ 3 million.

*Diagnosis of Hypertension Using Genetic Markers, NIH Grant # 1R43-HL-34915-01, 1987, US$ 50,000.

*Identification of the genetic mutations responsible for cystic fibrosis in the UAE, UAE University, 1994, #94/32, US$ 20,000.

Renin, insulin, phospholipase A2 gene polymorphisms and essential hypertension in the UAE, UAE University, 1994, US$ 20,000.

Glucokinase gene polymorphisms and non-insulin dependent diabetes mellitus and gestational diabetes in the UAE, UAE University, 1994, US$ 10,000.

*Identification of the genetic mutations responsible for schizophrenia in the UAE, UAE University, 1994, US$ 15,000.

*Identification of the genetic mutations responsible for cystic fibrosis in the UAE. Part 2, UAE University, 1995, #95/01, US$ 10,000.

*Molecular bases of essential hypertension in the UAE, UAE University, 1995, #95/10, US$ 20,000.

Molecular scanning of the glucokinase gene in diabetic subjects, UAE University, 1995, US$ 7,000.

Molecular basis of dyslipoproteinemiae in the UAE, UAE University, 1995, US$ 8,000.

*Identification of cystic fibrosis mutations in the UAE, UAE University, 1996, US$ 10,000.

*Molecular and genetic regulation of hypertension and ageing in the UAE, UAE University, 1996-1998, US$ 50,000.

*Involvement of the renin gene in hypertension in the United Arab Emirates, UAE University, 1998, #CP/98/07, US$ 15,000.

The role of endothelin-1 (ET-1) in cardiovascular diseases and hypertension amongst nationals of the United Arab Emirates, UAE University, 1998, #NP/98/09, US$ 10,000.

*Cystic fibrosis in the Gulf: mutations in the cystic fibrosis gene, clinical phenotype and genetic testing, UAE University, 1999-2002, #NP/99/02, US$ 30,000.

*Identification of mutations responsible for neurofibromatosis type 1 (NF1) in the UAE, UAE University, 1999, #NP/98/01, US$ 8,000.

Biochemical markers of hypertension in the United Arab Emirates population, UAE University, 1999, #NP/99/05, US$ 10,000.

*Molecular architecture of hypertension in a Pakistani population, URC Grant # 01-II/11/BBS, AKU, 2001-2004, US$ 48,019.

Association study of PON1 polymorphisms and stroke, URC Seed Money Grant # 02SF40096, AKU, 2002-2003, US$ 10,000.

Molecular genetic studies of Type II (non-insulin dependent) diabetes in the Pakistani population, URC Seed Money Grant # , AKU, 2002-2003, US$ 10,250.     

Screening the ABCA1 gene for novel mutations in patients with hypo-alpha-lipoproteinemia, URC Grant, AKU, 2003-2004, US$ 10,200.

*Screening of the paraoxonase gene cluster for novel mutations in patients with ischemic stroke, URC Grant #032039BBS, AKU, 2003-2006, US$ 25,000.

CFTR mutation analysis: Effect of the genotype on phenotype and mortality in Pakistani patients with cystic fibrosis, URC Grant #032032PAED, AKU, 2003-2006, US$ 19,200.

*Towards unraveling the molecular and genetic architectures of essential hypertension in Pakistan: a database of Pathan and Sindhi hypertensive families for the identification of genes implicated in hypertension by linkage analysis. Grant from the Service for Scientific and Education, French Embassy, Islamabad, Pakistan, 2004-2005, Euros 10,000.

*Generation of a functional stem cell line from human umbilical cord blood. Pakistan Science Foundation, Islamabad, 2004-2006, US$ 17,500.

Analysis of NPC1 expression by engrafted neural stem cells and clinical outcome in a Niemann-Pick Type C disease model. URC Grant #, AKU, 2004-2006, US$ 31,500.

Recurrence and reinfection of H. pylori implementation after eradication of H. pylori by using two different treatment options. URC Grant #, AKU, 2004-2006, US$ 31,000.

*The ATP-binding cassette transporter gene, VMD2 gene, and macular diseases. URC Grant # 041005BBS, AKU, 2004-2006, US$ 21,700.

Screening Pakistani patients for polycystic kidney disease 1 (PKD1) gene mutations. URC Grant #07115BBS, AKU, 2004-2005, US$ 9,450.

*The role of ABCA1 in cardio-vascular diseases in Pakistan. Cambridge University, UK, 2006-2007, UK£ 10,800.

*Cardio-vascular risk factors in Karachi (CRIK). Cambridge University, UK, 2006-2007, UK£ 53,000.

Molecular genetic studies in hypertension, type 2 diabetes and coronary heart disease in Pakistan. The Welcome Trust, UK, grant #WT080747AIA, UK£ 285,239, 2006-2011.

*MLH-1deficiency in colon cancers of Pakistan. Endowment from Ebrahim Family (Houston, TX, USA), 2006-2011, US$ 50,000.

*Karachi intra-cranial stenosis study (KISS) – a pilot phase study. URC Grant # SM070203, AKU, 2007-2008, US$ 10,000.

Risk assessment of cerebro-vascular events in Pakistan (RACE). Grant from Novo-Nordisk, 2007-2010, US$ 55,000.

*Pakistan Risk of Myocardial Infarction Study (PROMIS), Cambridge University, UK, UK£ 175.000 (USD 350,000), 2007-2008.

Cardio-vascular risk factors in Karachi (CRIK): a genome-wide association study for gene identification. Welcome Trust, UK, grant UK£ 1,450,000 (USD 2.9M), 2008-2009; additional research funds of UK£ 1,800,000 (USD 3.6M) provided by the Sanger Institute to complete the project; i.e., total award of UK£ 3.25M (USD 6.5M).

IBC Cardio-chip (60,000 SNPs at 2,095 gene loci validated for their role in CVDs) using the Illumina 55K array (http://investor.illumina.com) in the first 2,000 MI cases and 2,000 controls from PROMIS. Wellcome Trust Sanger Institute and University of Cambridge, 2008, £160,000 (USD 320,000).

Assessment of standard lipids in PROMIS 5,000 MI cases and 5,000 controls, British Heart Foundation, £90,000 (USD 180,000); 2008-2009.

Karachi Intra-cranial stenosis study (KISS). Higher Education Commission, Islamabad, Pakistan, 2008-2010, US$ 109,000.

Pakistan Risk of Myocardial Infarction Study (PROMIS), Cambridge University, UK£ 250,000 (USD 500,000); 2007-2010.

*Investigation of gene-lifestyle interactions on risk of confirmed first-ever myocardial infarction in South-Asians: a genome-wide association study in a Pakistani population, Wellcome Trust, UK, UK£ 1,5 M, 2008-2010; the Sanger Institute, UK, is also contributing additional funds of UK£ 1.8 M for this project; i.e., total award of UK£ 3.3 M (USD 6.5 M); 2008-2010.

*Establishment of a bio-resource for discovery and evaluation of genetic and other determinants of stroke in South Asia. NIH # 1R21NS064908-01, USD 215,000; 2009-2011.

Markers of the metabolic syndrome linking type 2 diabetes and MI in South Asia. NIH # 1RC1TW008485-01, USD 999,986; 2010-2012.


Vinogradov SN, Shlom JM, Kapp OH, Frossard PM (1981). Subunit structure of annelid extracellular hemoglobins. In Lamy and Lamy (eds) invertebrate oxygen-binding proteins: Structure, active site, and function. Marcel Dekker, Amsterdam, pp. 85-96.

Frossard PM (1981). Quaternary structure and function of the erythrocruorin of Eisenia fetida. In Lamy and Lamy (eds) invertebrate oxygen-binding proteins: Structure, active site, and function. Marcel Dekker, Amsterdam, 373-384.

Frossard PM, Coleman RT, Funke H, Assmann G (1987). Molecular genetics of the human apolipoprotein AI-CIII-AIV gene complex. Application to detection of susceptibility to atherosclerosis. In Hauss, Wissler, and Grunwald (eds) Recent advances in atherosclerosis research. Rhein-Westfal. Akad. Wissen. 76, Westdeutcher Verlag GmbH, Opladen, pp. 53-62.

Frossard PM, Vinogradov S (1989). Using DNA markers to predict genetic susceptibility to atherosclerosis. In Lusis and Sparkes (eds) Genetic factors in atherosclerosis: approaches and model systems. Monographs in human genetics, vol. 12, Karger, Basel, pp. 110-124.

Frossard Philippe (1991). The Lottery of Life. Bantam Press, London, New York, Toronto, Sydney, Auckland, 252 pages. Also published in France (Dunod, 1992; own translation), Japan (NHK, 1992) and Spain (Ediciones B, 1993).

Lester S, Dowse T, Frossard P, McCluskey J (1997). Arab Emirati Bedouin normotension. In Terasaki PI, Gjertson DW (eds.) HLA 1997, Publ. UCLA Tissue Typing Laboratory, Los Angeles, CA, p. 193.

Frossard PM, Parvez SH, Lestringant GG (1998). The molecular architecture of an individual’s genetic susceptibility to xenobiotics. In Reiss C, Parvez S, Labbe G and Parvez H (eds.) Advances in Molecular Toxicology, VSP International Press, Zeist, The Netherlands, pp. 517-528.

Frossard PM, Parvez SH, Obineche EN, Lestringant GG (1999). Molecular Genetics of Hypertension in an isolated Gulf Arab population. In Frossard PM, Parvez SH, Minami M, Parvez S and Saito H (eds.) Genetic, Immune and Molecular Predisposition to Hypertension. Progress in Hypertension, vol. 4, VSP International Press Zeist, Amsterdam, The Netherlands, pp. 83-136.

Frossard PM, Parvez SH, Minami M, Parvez S and Saito H (eds.) Genetic, Immune and Molecular Predisposition to Hypertension. Progress in Hypertension, vol. 4, VSP International Press Zeist, Amsterdam, The Netherlands, 1999, 267 pages.

Saeed M, Frossard PM, Parvez H (2005). Alzheimer’s disease: from bench to bedside. Advances in Neuroregulation and Neuroprotection (ANRNP), BRILL/VSP Academic Publishers, Leiden, Holland, pp. 43-62.

Unravelling the molecular and genetic architectures of human cardio-vascular disorders, with special emphasis on heart disease, hypertension, diabetes, obesity and atherosclerosis.

Mathematical modelling of complexity in biology in general and of complex human traits in particular.

Molecular bases of human diseases and disorders

Molecular genetics

Genetic Epidemiology

Research strategy and research programmes design

Grant funding



Numerous prizes and awards, among which:

UNESCO’s World’s Young Scientist Award, Göteborg, Sweden, 1971 (conferred ahead of the First Earth Summit held in Stockholm, Sweden, in 1972).

Knight of the French National Order of Merit, France, 2003 (conferred by French President Jacques Chirac).


Sole inventor on three patents issued in the USA and Europe:

  • US patent number US-4,772,549, 20 September 1988. Frossard PM: Polymorphisms related to lipid metabolism: APOB, APOCII, APOE, APOAIV.

  • US patent number US-4,801,531, 31 January 1989. Frossard PM: APOAI/CIII genomic polymorphisms predictive of atherosclerosis.

  • US patent number US-4,861,708-A, 29 August 1989. Frossard PM: Restriction fragment analysis of individuals using cardiovascular system probes (Genetic polymorphisms predictive of hypertension).

This information is private
        Share by: